CTOs on the Move

HiberCell

www.hibercell.com

 
Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.hibercell.com
  • 619 West 54th Street 8th Floor
    New York, NY USA 10019
  • Phone: 212.601.2800

Executives

Name Title Contact Details

Funding

HiberCell raised $60.7M on 02/07/2019
HiberCell raised $67.4M on 05/19/2021
HiberCell raised $30M on 05/19/2021

Similar Companies

Readcoor

ReadCoor is leading the next generation of `omics` by delivering the first panomic spatial sequencing platform to the global audience of researchers, clinicians, pharma and diagnostics companies, and ultimately patients. It is accomplishing this with a fundamental new technology called FISSEQ which simultaneously enables integration of high throughput sequencing, morphometric analysis, cellular location and three dimensional spatial imaging. This uniquely powerful tool is the first and only implementation of `In-situ Sequencing` and will revolutionize the next phase in understanding the transcriptome, introducing vast new opportunities for important and meaningful clinical insight. ReadCoor will fulfill the mission with a comprehensive set of high quality services, systems and actionable information provided to research and healthcare communities worldwide. Current transcriptomic tools are cumbersome, inadequate and cannot preserve the rich panomic information contained in cellular structures. ReadCoor combines both next generation sequencing and morphometric information for the first time in a new generation sequencing platform that enables researchers to perform high throughput RNA sequencing without dissociating cells, thus preserving important cellular structures, pinpointing transcripts to individual cells in 3D, and delivering high fidelity spatial image data.

Cell Biosciences Inc

Cell Biosciences Inc is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BridgeBio

We are a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases.

Cerapedics

i-FACTOR Peptide Enhanced Bone Graft is a drug/device combination that creates a new category of bone graft technology. Take a moment to review our introduction to i-FACTOR, our Level-1 IDE study and comparative performance sections given below.

Nohla Therapeutics

Nohla Therapeutics is a cellular therapy company driven to provide leading off the shelf therapies for patients with critical diseases. Nohla’s first product is a universal donor cell therapy targeting hematopoietic recovery and chemotherapy induced neutropenia, and is being extended to treat a range of other medical indications. This and other products in the pipeline are based on a unique umbilical cord blood expansion platform developed at the Fred Hutchinson Cancer Research Center